Showing 6201-6210 of 7664 results for "".
- Merz Rolls Out Belotero Balance(+) with Lidocaine in the UShttps://practicaldermatology.com/news/merz-rolls-out-belotero-balance-with-lidocaine-in-the-us/2460675/Merz Aesthetics is launching Belotero Balance(+) with Lidocaine in the US. “Healthcare providers can now rely on the well-known rheological properties and performance of Belotero Balance with the time savings and consistency of a pre-mixed lidocaine formulation,” says Patric
- NRS Survey Finds Rosacea Patients Lack Knowledge of Antibiotic Resistancehttps://practicaldermatology.com/news/nrs-survey-finds-rosacea-patients-lack-knowledge-of-antibiotic-resistance/2460671/A majority of rosacea patients have never heard of antibiotic resistance, results of a recent survey by the National Rosacea Society (NRS) show. Yet topical or oral antibiotics are among the most commonly prescribed treatments for rosacea. The NRS’s rec
- Verrica: Post-Hoc Analyses Show Benefits of VP-102 at Specific Siteshttps://practicaldermatology.com/news/verrica-post-hoc-analyses-show-benefits-of-vp-102-at-specific-sites/2460661/Positive data from post-hoc pooled analyses of the pivotal Phase 3 CAMP trials demonstrate the safety and efficacy of Verrica Pharmaceuticals’ lead product candidate VP-102 in molluscum contagiosum (molluscum) in specific body regions. The data were presented in poster format online for the
- RealSelf Acquires Tajmeeli.com to Serve Arabic-Speaking Medical Aesthetics Markethttps://practicaldermatology.com/news/realself-acquires-tajmeelicom-to-aerve-arabic-speaking-medical-aesthetics-market/2460660/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- SBS Part 1: The Medical Dermatology Summit to Kick Off February 4https://practicaldermatology.com/news/sbs-part-1-the-medical-dermatology-summit-to-kick-off-february-4/2460659/SBS Part I: The Medical Dermatology Summit will offer complimentary direct access to leading academic experts, clinical leaders, researchers, and more through live-streamed and interactive sessions as well as on-deman
- Study: Acute Itching in AD Linked to Environmental Triggershttps://practicaldermatology.com/news/study-acute-itching-in-ad-linked-to-environmental-triggers/2460658/Allergens in the environment often are to blame for episodes of acute itch in eczema patients, and that this itching often doesn’t respond to antihistamines because the itch signals are being carried to the brain along a previously unrecognized pathway that current drugs don’t ta
- Fitness Level Tied to Psoriasis Riskhttps://practicaldermatology.com/news/fitness-level-tied-to-psoriasis-risk/2460653/Low fitness levels may increase risk for psoriasis, according to a register-based study of military recruits. Specifically, male recruits to compulsory military training who were rated as the least fit had a 35 percent higher risk for psoriasis when compared to the f
- DermBiont Releases Positive Phase 2 Data for DBI-001 in Tinea pedis, Atopic dermatitishttps://practicaldermatology.com/news/dermbiont-releases-positive-phase-2-data-for-dbi-001-in-tinea-pedis-atopic-dermatitis/2460649/Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer DermBiont. In the phase 2b clinical study of DBI-001 in tinea p
- Soliton Appoints Sean J. Shapiro as Vice President of Saleshttps://practicaldermatology.com/news/soliton-appoints-sean-j-shapiro-as-vice-president-of-sales/2460643/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.